Clinical evaluation examines pentraxin 3 as a predictive marker for severe fibrosis and carotid intima-media thickness in MAFLD patients, indicating potential noninvasive monitoring value.
Background and objectivesMetabolic-associated fatty liver disease (MAFLD) may increase the risk of cardiovascular events. In this study, we assessed the predictive value of pentraxin 3 (PTX3) for severe fibrosis and carotid intima-media thickness (CIMT) in patients with MAFLD.
No takes yet. Share an insight, caveat, or question.
Hassnine et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: